Evidence map›Paper›PMID 41221989›Full record

ArticleACR open rheumatology2025

Characterization of the Fecal Metabolome in Patients With Early Systemic Sclerosis.

Arissa C Young, Kristofer Andréasson, Jennifer Labus, Nedas Matulionis, Jonathan P Jacobs, Heather Christofk, Elizabeth R Volkmann

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACR open rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Arissa C YoungUniversity of California, Los Angeles.ORCID https://orcid.org/0000-0002-0612-0498
Kristofer AndréassonLund University, Lund, Sweden.ORCID https://orcid.org/0000-0001-7021-2541
Jennifer LabusUniversity of California, Los Angeles.
Nedas MatulionisUniversity of California, Los Angeles.
Jonathan P JacobsUniversity of California, Los Angeles.
Heather ChristofkUniversity of California, Los Angeles.
Elizabeth R VolkmannUniversity of California, Los Angeles.ORCID https://orcid.org/0000-0003-3750-6569

Funding

Identifying predictors of treatment response in systemic sclerosis-related interstitial lung diseaseK23HL150237 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VOLKMANN, ELIZABETH R · 2020 to 2024
$910k
Anna-Greta Crafoords Stiftelse för Reumatologisk Forskning 20242014NHLBI NIH HHS K23 HL150237
6 · The paper itself

Abstract

objectiveTo evaluate the fecal metabolome in patients with early systemic sclerosis (SSc) compared with unaffected controls and to determine if altered metabolites are associated with specific bacterial genera in patients with early SSc.

methodsStool samples and clinical data were collected from 106 patients with early SSc and 79 unaffected control patients. Targeted metabolomics was performed on fecal samples using liquid chromatography mass spectrometry, and 16S ribosomal RNA gene sequencing was used to determine the microbial composition of fecal samples.

resultsCompared with unaffected controls, patients with early SSc had higher levels of nicotinamide, 5'-methylthioadenosine, and several short-chain fatty acids (SCFAs) including valeric acid, propionic acid, and caproic acid. Conversely, patients with early SSc had lower levels of xylonic acid, orotate, methionine sulfoxide, and sarcosine. SCFAs were associated with unique bacterial genera, several of which were more abundant in patients with SSc compared with unaffected controls.

conclusionThe fecal metabolome is altered in patients with early SSc, with a shift toward increased SCFAs.

Identifiers

PMID41221989
PMCPMC12606447

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.